SAN DIEGO--(BUSINESS WIRE)--Feb. 4, 2021--
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Thursday, February 18, 2021 at 11:00am ET to discuss GB004, its oral HIF-1α stabilizer for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC).
Gossamer management will present alongside key IBD and HIF biology opinion leaders, including:
William Sandborn, M.D., Director of the Inflammatory Bowel Disease Center and Chief of the Division of Gastroenterology at UC San Diego Health
Silvio Danese, M.D., Ph.D., Unit Director of the Inflammatory Bowel Disease Clinical and Research Unit at Humanitas Research Hospital, Milan, Italy
Cormac Taylor, Ph.D., Professor of Cellular Physiology at University College Dublin
As part of the event, Gossamer Bio management and Drs. Sandborn, Danese, and Taylor will be available for questions.
William Sandborn, M.D., is a board-certified gastroenterologist, who is one of the world's top experts in the management of ulcerative colitis and Crohn’s disease. He directs the Inflammatory Bowel Disease Center at UC San Diego Health. In addition, he is Chief of the Division of Gastroenterology for UC San Diego Health. A Professor in the Department of Medicine at UC San Diego School of Medicine, Dr. Sandborn conducts clinical trials in IBD and leads a team of physicians, research fellows, nurses, and study coordinators. His clinical trials have been instrumental to developing modern treatments for IBD. Dr. Sandborn has published 836 articles in prestigious journals, including the New England Journal of Medicine, The Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. Prior to joining UC San Diego Health, Dr. Sandborn worked in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. Dr. Sandborn completed his fellowship at Mayo Clinic. He did his residency and earned his medical degree at Loma Linda University School of Medicine.
Silvio Danese, M.D., Ph.D., is the Head of the Inflammatory Bowel Disease Center at Humanitas Research Hospital and the group leader of the Gastrointestinal Immunopathology Laboratory at Humanitas Research Center in Milan, Italy. A Professor of Gastroenterology at Humanitas University, his main research area of interest is the investigation of the fundamental mechanisms underlying IBD pathogenesis. He served as President of the European Crohn’s and Colitis Organization (ECCO) in 2019 and has served as the Principal Investigator on many Phase 1, 2 and 3 clinical trials for the treatment of IBD patients. He is also Member of the Editorial Board of Current Drug Target and Alimentary Pharmacology & Therapeutics and Associate Editor of Gut and Journal of Crohn’s and Colitis. He has published more than 300 research articles in peer-reviewed journals with high impact factor. He trained in gastroenterology at Policlinico Gemelli, Rome, Italy, and earned his Ph.D. there in 2004. Professor Danese also worked in Professor Claudio Fiocchi’s laboratory at the Case Western Reserve University, Cleveland, Ohio from 2001 to 2004.
Cormac Taylor, Ph.D., is a Professor of Cellular Physiology at the School of Medicine and Medical Science and the Conway Institute, University College Dublin, Ireland. He leads the Taylor Lab, in which research is directed towards expanding the understanding of the physiological and pathophysiological mechanisms by which changes in micro-environmental oxygen levels regulate gene transcription in cells. A key focus of this work is the identification of new therapeutic targets in inflammatory bowel disease. Dr. Taylor was elected as a Member of the Royal Irish Academy in 2014. He was awarded the 2014 Nature mid-career mentorship award and the 2017 Takeda Distinguished Researcher Award from the American Physiological Society. He has authored over 130 articles in journals including Gastroenterology, Gut, PNAS and Science and is an Editorial Board Member of the American Journal of Physiology and the Journal of Biological Chemistry. Dr. Taylor received his Ph.D. in Pharmacology from UCD in 1996 prior to a postdoctoral fellowship at Harvard Medical school from 1996-2001 and has been running his own independent research group since 2001.
Conference Call and Webcast
Gossamer will host a conference call and live audio webcast at 11:00 am ET on Thursday, February 18. The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:
Conference ID: 6135079
Domestic Dial-in Number: (833) 640-7726
International Dial-in Number: (602) 585-9912
Live Webcast: https://edge.media-server.com/mmc/p/9tbs35gb
A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005067/en/
For Investors and Media:
Bryan Giraudo, Chief Financial Officer
Gossamer Bio Investor Relations
Source: Gossamer Bio, Inc.